In-house members
10
Total footprint
15,000 sq ft
The incubator where it all started, our St Philips incubator is typically home to earlier-stage Deep Tech teams of around 10-20 and has been the launchpad for many success stories — from startups scaling to bigger facilities to game-changing company exits.
Work alongside pioneering startups tackling global issues — from next-generation battery materials and better diabetes treatments to quantum-enabled cameras that track greenhouse gas leaks.
Our St Philips incubator (previously Unit DX) opened in 2017 to improve access to lab space and facilities for scientific companies in Bristol.
Just a 10-minute walk from Bristol Temple Meads train station, the space combines purpose-built laboratories, flexible offices and cutting-edge instrumentation.
Rent an entire lab or just a lab bench; have a private office or share one — and access our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.
Get in touch if you are after shared or private lab space at St Philips or browse our other sites for more private lab space.
Travel between locations is measured in walking distance
Albert Rd
0.5 miles / 11 min
0.7 miles / 15 min
Hone Bio is revolutionising drug delivery using lipid nanoparticles (LNPs) and exploring their potential across multiple therapeutics, including cell and gene therapies, vaccines and autoimmune diseases. Its NanoPilot platform technology engineers LNPs to target specific cell types with extreme precision to optimise drug effectiveness by minimising off-target effects that tend to accumulate in the liver. This unlocks new possibilities for using LNPs to safely treat diseases in other parts of the body that require maximum target specificity in their drug delivery.
Lifecare is committed to improving the lives of people and pets with diabetes. It is developing the next-generation of miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers to the market. The company’s spin-off entity Lifecare Chemistry Ltd was founded to enhance research collaboration and secure ownership of its improved analyte-specific chemical receptor developments.
Glaia is developing innovative solutions to optimise agricultural plant performance to help food security and fight climate change. Using disruptive technology, its sustainable agrochemicals unlock the potential of the photosynthetic process, enabling plant cells to more efficiently convert energy to biomass to increase crop yields without increasing inputs. This results in greater profits for growers and reduced greenhouse emissions, delivering more sustainable global food production.
Zentraxa is precision engineering biomaterials, pushing the boundaries of biopolymer synthesis to develop sustainable, performance-enhancing ingredients for everyday products. Its proprietary technological platform (Zentide) overcomes the biodesign limits of existing, conventional peptide synthesis by designing, producing and testing complex, novel peptides with one universal process. Zentraxa creates bespoke solutions for a range of industries by combining key features from different naturally-occurring proteins, such as stiffness, adhesion or thermal stability.
NuNano is advancing the field of atomic force microscopy with high-precision probes for nanometer-scale imaging. Its proprietary microfabrication processes produce reliable, high-quality probes with market-leading dimensional tolerances. It also provides dedicated support to its customers, from probe selection to storage, for a seamless user experience.
Carbometrics is striving to improve diabetes patient care by enhancing technology for continuous glucose monitoring. The team aims to pave the way for a new class of highly-accurate sensors with its groundbreaking synthetic molecule that is both chemically stable and able to bind to glucose in the blood. This follows on from the work of exited startup Ziylo Ltd, which was Science Creates’ very first resident and acquired by Novo Nordisk in 2018.
CellVoyant is accelerating the development of novel stem cell-based therapies for chronic diseases. Its technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, enable advanced cell analytics and ultimately unlock the controllable manufacturing of any cell and tissue in the body at scale. Built on foundational research at the University of Bristol, CellVoyant works at the intersection of cell biology, computing, engineering and machine learning to carry out its mission.
CoED Biosciences is transforming human tissue separation for adoptive cell therapy and research purposes. Its Column of Expansion and Differentiation (CoED) device harnesses the power of chemotaxis and gravity to gently purify and extract immune cells from blood or tumour biopsies. The process preserves both the integrity and functionality of the tissues without the need for magnets or centrifugation, saving valuable time and resources.
Folium Science is increasing agricultural productivity by enhancing animal welfare and feed efficiency in livestock farming while reducing environmental impact. Its unique CRISPR-Cas technology platform harnesses natural biological systems to safely modulate animal microbiomes by regulating metabolic functions and targeting unwanted bacteria with extreme precision. This approach helps reduce reliance on antibiotics and can be applied to both plants and soil to improve their bacterial biomes for optimal growing conditions.
.webp)